EcoR1 Capital, LLC, a 10% owner of Atara Biotherapeutics, Inc. (ATRA), made a significant purchase of company stock on May 7, 2026. The filing shows EcoR1 Capital acquired 507,407 shares at a price of $9.35 per share, representing a total investment of approximately $4.74 million.
This substantial acquisition by a major stakeholder is often viewed as a strong indicator of the insider's confidence in the company's future performance and prospects. The purchase comes amidst other recent insider transactions for ATRA, including sales by James Huang and Panacea Innovation Ltd earlier in the week.
Atara Biotherapeutics is a clinical-stage biopharmaceutical company developing allogeneic T cell therapies for patients with severe diseases. The company's pipeline focuses on oncology and autoimmune indications.